0. DOCID:29859 SCORE: 0.000560658079479883
DOCNO: 16214043
OWNER: NLM
STATUS: In-Process
AUTHOR: George R P Blackledge GR
AFFILIATION: AstraZeneca Pharmaceuticals, Medical Oncology, Alderley House, Alderley Park, Macclesfield, Cheshire SK10 4TF, UK. george.blackledge@astrazeneca.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: European journal of cancer (Oxford, England : 1990)
COUNTRY: England
TITLE: The difficulties industry is facing with investigators.
PUBDATE: 20051001
The number of new agents being developed for the treatment of cancer has, over the past 10 years, increased dramatically which has resulted in increased interactions between the pharmaceutical industry that discover and develop most new agents and investigators in academic institutions, hospitals and office practices. This close interaction has inevitably led to a number of issues being identified on both sides and this paper will attempt to identify some of these and propose solutions.


1. DOCID:30836 SCORE: 0.00056062618167447
DOCNO: 14719075
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Apoptosis
QUALIFIER: pathology
AUTHOR: Luca Giannetti L
AUTHOR: Ugo Consolo U
AUTHOR: Cristina Magnoni C
AUTHOR: Lorenzo Lo Muzio L
AFFILIATION: Institute of Dentistry and Surgery, Faculty of Medicine, University of Modena, Modena, Italy.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Oncology reports.
COUNTRY: Greece
TITLE: Apoptosis: escaping strategies in human skin cancer (Review).
PUBDATE: 20040201
Apoptosis must be considered a rescue mechanism that controls the integrity of the cell erasing aberrant clones and it is likely that failure of apoptosis constitutes a key factor responsible for tumour formation, progression and resistance to drugs. Several genes (e.g. survivin, bcl-2 family, p53) are involved in these pathways. Much work still needs to be done to identify the molecular pathway of apoptosis resistance but restoration of the apoptotic response represents a crucial new therapeutic target for cancer treatment.


2. DOCID:31995 SCORE: 0.000560622412442402
DOCNO: 15990438
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: Laura Biganzoli L
AUTHOR: Matti Aapro M
AFFILIATION: Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy.
PUBTYPE: Journal Article
JOURNALTITLE: Gynäkologisch-geburtshilfliche Rundschau.
COUNTRY: Switzerland
TITLE: Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy.
PUBDATE: 20050601
Older women have unfortunately been underrepresented in breast cancer clinical trials, with the majority of studies being restricted to patients younger than 70 years. Elderly patients are an inhomogeneous group and frequently suffer from comorbidities and/or impaired organ functions. These facts may often lead to death from causes other than cancer, thus nullifying any possible benefit of adjuvant treatment; furthermore, they render extrapolation of standard treatment recommendations to the elderly potentially hazardous, particularly with respect to chemotherapy. Specific clinical trials are therefore needed to investigate adjuvant treatments tailored for the heterogeneous older population.


3. DOCID:31299 SCORE: 0.000560606432982901
DOCNO: 12648714
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: radiotherapy
QUALIFIER: methods
QUALIFIER: radiotherapy
AUTHOR: A Belliere A
AUTHOR: O Chapet O
AUTHOR: R Coquard R
AUTHOR: P Romestaing P
AUTHOR: J M Ardiet JM
AUTHOR: J P Gérard JP
AFFILIATION: Service de radiothérapie, CH Lyon-Sud, 69495 cedex, Pierre-Bénite, France.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer radiothérapie : journal de la Société française de radiothérapie oncologique.
COUNTRY: France
TITLE: [Brachytherapy in carcinomas of anal canal and rectum: techniques and results]
PUBDATE: 20030201
Conservative treatment of small anal canal and low rectal cancers is a valid alternative to radical surgery through combinated strategies including external beam and/or intracavitary irradiation, concomitant chemotherapy and 192 iridium implantation as a booster dose. Feasibility, tolerance and results are effective. Local control of the disease and the quality of the anal functions are good. The treatment requires great care in patient selection and follow-up.


4. DOCID:30271 SCORE: 0.00056057451505548
DOCNO: 15283157
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: antagonists & inhibitors
QUALIFIER: therapeutic use
AUTHOR: Yorifumi Satou Y
AUTHOR: Masao Matsuoka M
AFFILIATION: Institute for Virus Research, Kyoto University.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: Japan
TITLE: [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells]
PUBDATE: 20040701
The proteasome is a multicatalytic proteinase complex responsible for the degradation of most intracellular proteins, including crucial to cell cycle regulation, cell growth, and apoptosis. Bortezomib (Vercade; formerly known as PS-341) is a novel dipeptide boronic acid that is the first proteasome inhibitor to have progressed to clinical trials. Below we discuss the mechanism of bortezomib for cancer therapy, review the clinical data, and introduce the potent effect on ATL cells.


5. DOCID:31391 SCORE: 0.000554510446091678
DOCNO: 15389379
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: U Lehmann U
AUTHOR: F Länger F
AUTHOR: G Celikkaya G
AUTHOR: H J Lück HJ
AUTHOR: H Kreipe H
AFFILIATION: Institut für Pathologie, Medizinische Hochschule Hannover.
PUBTYPE: Journal Article
JOURNALTITLE: Zentralblatt für Gynäkologie.
COUNTRY: Germany
TITLE: [Epigenetic changes in breast cancer shown by aberrant promoter methylation]
PUBDATE: 20040801
The aberrant methylation of cytosine residues in the promoter region of growth-regulatory genes is now recognized as an important inactivation mechanism in addition to deletion and mutation in the development and progression of cancer. Principally all pathways regulating proliferation and differentiation, which are perturbed in cancer cells, can be affected. In breast cancer epigenetic inactivation is a frequent and early event displaying great quantitative gene-specific differences during progression. The occurrence of specific aberrant methylation patterns is associated with the histological grade and subtype of mammary carcinoma biopsies.


6. DOCID:31442 SCORE: 0.000538892216188372
DOCNO: 12242108
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Nuclear Proteins
DESCRIPTOR: Saccharomyces cerevisiae Proteins
QUALIFIER: chemistry
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: Kristen E Neely KE
AUTHOR: Jerry L Workman JL
AFFILIATION: Howard Hughes Medical Institute and Department of Biochemistry and Molecular Biology, The Pennsylvania State University, 306 Althouse Laboratory, University Park, PA 16802, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Biochimica et biophysica acta.
COUNTRY: Netherlands
TITLE: The complexity of chromatin remodeling and its links to cancer.
PUBDATE: 20021001
The relief of chromatin-mediated repression by ATP-dependent chromatin-remodeling complexes is an important step in the proper transcriptional regulation of many genes. This review gives an organized summary of this large group of complexes that exist in yeast, flies, and humans. Their subunit composition and brief overview of their functional properties will be discussed. Also, current links between human chromatin-remodeling complexes and cell growth and cancer will be presented.


7. DOCID:29356 SCORE: 0.000528563784281027
DOCNO: 15542423
AUTHOR: Michael R Freeman MR
AFFILIATION: Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, Enders Research Laboratories, Suite 1161, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. michael.freeman@childrens.harvard.edu
PUBTYPE: Comment
PUBTYPE: Journal Article
JOURNALTITLE: Cancer cell.
COUNTRY: United States
TITLE: HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?
PUBDATE: 20041101
In this issue of Cancer Cell, Mellinghoff et al. (2004) demonstrate that a small molecule inhibitor of the EGF receptor (EGFR) and the HER2/ErbB2/c-Neu kinase blocks signaling to the androgen receptor by a mechanism that involves HER2/HER3 heterodimerization. Surprisingly, the EGFR is peripheral to this signaling mechanism. These results have implications for the design of targeted therapy for hormone-refractory prostate cancer.


8. DOCID:31215 SCORE: 0.000420056242400598
DOCNO: 12084224
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Therapy
DESCRIPTOR: Immunotherapy
QUALIFIER: therapy
AUTHOR: Ingo Kausch I
AUTHOR: Peter Ardelt P
AUTHOR: Andreas Böhle A
AUTHOR: Timothy L Ratliff TL
AFFILIATION: Department of Urology, Medical University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current urology reports.
COUNTRY: United States
TITLE: Immune gene therapy in urology.
PUBDATE: 20020201
Effective treatments are needed urgently for metastatic disease in bladder, prostate, and renal cell cancer. In the past few years, several new approaches for treating these conditions have been proposed, including gene therapy. A number of different strategies have been developed to accomplish urologic cancer gene therapy. Genetic immunomodulation strategies attempt to activate immune defense mechanisms against tumor cells by transfer of tumor antigens, cytokine genes, or strongly immunogenic cell surface molecules. In this review, we illustrate the recent developments in immune gene therapy.


9. DOCID:29622 SCORE: 0.00039439707427428
DOCNO: 14750163
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genomic Instability
DESCRIPTOR: Repressor Proteins
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: Stefan Duensing S
AUTHOR: Karl Münger K
AFFILIATION: Molecular Virology Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA. duensing@pitt.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: International journal of cancer. Journal international du cancer.
COUNTRY: United States
TITLE: Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins.
PUBDATE: 20040301
Genomic instability is a hallmark of most human cancers including high-risk human papillomavirus (HPV)-associated anogenital neoplasia. The two HPV-encoded oncoproteins, E6 and E7, can independently induce chromosomal abnormalities. We summarize the current state of knowledge concerning HPV-induced genomic instability and discuss its significance in the context of human carcinogenesis.


10. DOCID:29086 SCORE: 0.000354028373469021
DOCNO: 12636727
OWNER: NLM
STATUS: PubMed-not-MEDLINE
AUTHOR: Bao-Quan Ai BQ
AUTHOR: Xian-Ju Wang XJ
AUTHOR: Guo-Tao Liu GT
AUTHOR: Liang-Gang Liu LG
AFFILIATION: Department of Physics, ZhongShan University, GuangZhou, People's Republic of China.
PUBTYPE: Journal Article
JOURNALTITLE: Physical review. E, Statistical, nonlinear, and soft matter physics .
COUNTRY: United States
TITLE: Correlated noise in a logistic growth model.
PUBDATE: 20030201
The logistic differential equation is used to analyze cancer cell population, in the presence of a correlated Gaussian white noise. We study the steady state properties of tumor cell growth and discuss the effects of the correlated noise. It is found that the degree of correlation of the noise can cause tumor cell extinction.


11. DOCID:29247 SCORE: 0.000325926077846379
DOCNO: 15103275
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Tomography, Emission-Computed
QUALIFIER: radionuclide imaging
QUALIFIER: etiology
QUALIFIER: radionuclide imaging
QUALIFIER: etiology
AUTHOR: L Guilloton L
AUTHOR: D Rabar D
AUTHOR: J Honnorat J
AUTHOR: A Drouet A
AUTHOR: M Pavic M
AUTHOR: D Felten D
AFFILIATION: Service de Neurologie, HIA Desgenettes, Lyon. lss.guilloton@wanadoo.fr
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Revue neurologique.
COUNTRY: France
TITLE: [Paraneoplasic pandysautonomia with anti-Hu antibodies: a presentation of pulmonary adenocarcinoma identified by PET scanning]
PUBDATE: 20040401
A 74-year-old man developed pandysautonomia with severe orthostatic hypotension. Search for a paraneoplastic etiology was confirmed with the positivity of anti-Hu antibodies. [18] Fluorodeoxyglucose positron emission tomography (PET) enabled recognition of a lung adenocarcinoma. We emphasize the usefulness of PET scans for early diagnosis of cancer.


12. DOCID:30957 SCORE: 0.000296184195117911
DOCNO: 15086060
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: therapy
AUTHOR: Philippe Rougier P
AUTHOR: Marie-Christine Clavero-Fabri MC
AUTHOR: Emmanuel Mitry E
AFFILIATION: Hépato-gastro-entérologie, oncologie digestive, hôpital Ambroise Paré, 92104 Boulogne. philippe.rougier@apr.ap-hop-paris.fr
PUBTYPE: Journal Article
JOURNALTITLE: La Revue du praticien.
COUNTRY: France
TITLE: [Colorectal cancer management]
PUBDATE: 20040101
Colorectal cancer is a frequent disease with an increasing incidence. Its prognosis improved recently because of progress in diagnostic and therapeutic procedures. Rationale and guidelines for colorectal cancer screening using the faecal occult blood test in the average risk population and screening recommendations for high risk groups are presented, as well as diagnostic and therapeutic principles. Because of the efficacy of the new chemotherapy regimens, the availability of biotherapies and the fact that surgery can potentially cure more and more patients, colorectal cancer management needs to be multidisciplinary.


13. DOCID:30524 SCORE: 0.000294800204794315
DOCNO: 14563119
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: physiology
QUALIFIER: etiology
AUTHOR: Michael T McManus MT
AFFILIATION: Center for Cancer Research, Massachusetts Institute of Technology, 40 Ames Street, Cambridge, MA 02139, USA. mmcmanus@mit.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in cancer biology.
COUNTRY: United States
TITLE: MicroRNAs and cancer.
PUBDATE: 20030801
The general basis of cancer is the loss of cell identity and inappropriate proliferation of cells. Classically, a universal paradigm in oncogenesis is the accumulation of mutations in the open reading frames of protein-encoding oncogenes and tumor suppressors. The identification of new classes of noncoding RNAs (ncRNA) important for development and cell homeostasis will likely change this current paradigm. Recent data suggests that a special class of ncRNAs called microRNAs might be involved in human disease. This review proposes a role for microRNAs in oncogenesis.


14. DOCID:30073 SCORE: 0.000288823005870941
DOCNO: 14641193
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiography
AUTHOR: Sophia Zadelis S
AUTHOR: Nehmat Houssami N
AFFILIATION: Sydney-Square Breast Clinic, Medical Benefits Fund, School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
PUBTYPE: Journal Article
JOURNALTITLE: Australasian radiology.
COUNTRY: Australia
TITLE: Mammographic features of breast cancer in young symptomatic women.
PUBDATE: 20031201
The present study provides a descriptive analysis of the mammographic appearance of breast cancer in women aged 30-39 years presenting with symptoms, based on 65 cancers confirmed with histology. We correlate the findings with clinical presentation and histological findings. We describe, categorize and illustrate the different lesions seen on mammography. Our study shows that microcalcification, with or without associated masses, is a dominant feature of breast cancer visualized on mammography in women in this age group.